PL BioScience Unveils World's First Artificial Human Platelet Lysate

PL BioScience GmbH, a German life science firm, has announced a pioneering breakthrough in cell culture technology. In collaboration with DewCell Biotherapeutics, a Korean biotech expert in artificial platelet production, the company introduced the first-ever artificial Human Platelet Lysate (HPL). This development marks a significant leap, providing a fully lab-made and scalable alternative to traditional cell culture supplements.

This artificial HPL is produced using a proprietary method that enhances cell performance compared to its natural counterpart, offering a consistent and safer option for biopharmaceutical applications. The innovative solution is set to be presented at the International Society for Cell & Gene Therapy conference in New Orleans.

The fully artificial HPL aims to replace animal-derived supplements like Fetal Calf Serum with a scalable and ethical alternative. PL BioScience's solution aligns with the growing demand for sustainable laboratory practices and promises advancements in cell therapy and regenerative medicine.